6533b857fe1ef96bd12b3935

RESEARCH PRODUCT

Does Tocilizumab Indeed Reduce the Frequency of Th17 Cells? Comment on the Article by Thiolat et al

Paul OrnettiBernard BonnotteNona JanikashviliSylvain AudiaMaxime SamsonJean-francis Maillefert

subject

business.industryImmunologyArthritismedicine.diseasechemistry.chemical_compoundTocilizumabRheumatologychemistryAntigenImmunologyImmunology and AllergyMedicineExperimental pathologybusinesshttps://doi.org/10.1002/art.38718